Jeito Capital Becomes a Significant Investor in HI-Bio, a Clinical-stage Biotech Company Developing Targeted Therapies for Patients with Severe Immune-mediated Diseases

Paris, France, Nov. 1 (Korea Bizwire) - Jeito Capital (“Jeito”), a leading independent international private equity firm dedicated to biopharma, announced today that it has participated in the $120 million financing of Human Immunology Biosciences (HI-Bio™), a clinical-stage biotech company developing targeted therapies for patients suffering from severe immune-mediated diseases (IMD). Jeito Capital joins a syndicate of world class [...]